Stay updated on Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization of the ClinicalTrials.gov data ingest has been postponed from June 2025 to July 2025, and the revision number has been updated from v2.16.2 to v2.16.4.SummaryDifference1.0%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check48 days agoChange DetectedThe page has removed an erratum related to a previously mentioned study on pembrolizumab dosing in cancer patients.SummaryDifference0.3%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check76 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed study information regarding pembrolizumab (MK-3475) and its comparison to docetaxel in treating non-small cell lung cancer (NSCLC). Additionally, new identifiers and a revision number have been added.SummaryDifference24%
Stay in the know with updates to Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial page.